Morgan Stanley’s ACELYRIN SLRN Stock Holding History

Morgan Stanley’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-275,815	Closed	-$681K	–	8260
2025 Q1	$681K	Sell	275,815 -2,047,706	-88%	-$4.87M	﹤0.01%	5187
2024 Q4	$7.3M	Buy	2,323,521 +537,068	+30%	+$2.6M	﹤0.01%	3662
2024 Q3	$8.81M	Buy	1,786,453 +533,637	+43%	+$2.76M	﹤0.01%	3529
2024 Q2	$5.52M	Buy	1,252,816 +587,153	+88%	+$2.75M	﹤0.01%	3793
2024 Q1	$4.49M	Sell	665,663 -1,097,775	-62%	-$8.34M	﹤0.01%	3993
2023 Q4	$13.2M	Buy	1,763,438 +1,513,865	+607%	+$12.9M	﹤0.01%	3696
2023 Q3	$2.54M	Buy	249,573 +231,519	+1,282%	+$4.92M	﹤0.01%	4241
2023 Q2	$377K	Buy	+18,054	New	+$369K	﹤0.01%	5358

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's SLRN Position: Q2 2025 in Review

Morgan Stanley sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 275,815 shares — an estimated $681K sold.

Morgan Stanley first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $13.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Morgan Stanley reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Morgan Stanley sold 275,815 ACELYRIN shares in Q2 2025, an estimated $681K.
Morgan Stanley first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Morgan Stanley's ACELYRIN position peaked at $13.2M in Q4 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.